
Becton Dickinson
BDX · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $59,4 bn
- Div. yield
- 1,6%
- Year to date
- +42,9%
Ratio score
based on 8 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
2 ✓ · 2 — · 4 ✕ · 2 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 51,8 | 41,5 | 25,1 |
| Forward P/E | 14,9 | — | 16,2 |
| PEG | −27,1 | — | 2,2 |
| P/S | 2,9 | 3,4 | 2,2 |
| EV/EBITDA | 16,4 | 18,5 | 17,3 |
| P/FCF | 21,5 | — | 19,5 |
| P/B | 2,4 | 2,6 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 21 analysts
- Buy
- 12
- Hold
- 8
- Sell
- 1
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q4 2026 | 4,11 | 4,15 | Up +1,0% |
| Q3 2026 | 3,17 | 3,23 | Up +1,8% |
| Q2 2026 | 2,80 | 2,90 | Up +3,5% |
| Q1 2026 | 2,84 | 2,91 | Up +2,4% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,98 bn | 4,71 bn | 5,25 bn | 5,89 bn | 5,51 bn | 5,27 bn | 5,17 bn | 5,44 bn | 4,99 bn | 5,05 bn | 4,71 bn | 5,09 bn |
| EPS | 1,37 | −1,11 | 1,34 | 1,72 | 2,00 | 1,07 | 1,04 | 1,37 | 1,68 | 1,85 | 0,96 | 0,34 |
| Margin | 7,6% | −6,6% | 7,3% | 8,4% | 10,4% | 5,8% | 5,9% | 7,4% | 9,8% | 10,6% | 6,0% | 2,1% |
| FCF | 633 m | — | — | 1,00 bn | 1,05 bn | 35,0 m | 588 m | 882 m | 1,12 bn | 380 m | 739 m | 1,03 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $3,38 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| polen thomas e jr5 Nov 2026 · sale | $628 530 | 2 993 | $210,00 |
| feld michael26 Oct 2026 · sale | $15 058 | 76 | $198,13 |
| feld michael28 Sep 2026 · sale | $13 961 | 76 | $183,70 |
| feld michael26 Aug 2026 · sale | $31 101 | 165 | $188,49 |
| polen thomas e jr13 Aug 2026 · sale | $768 120 | 4 152 | $185,00 |
| goette roland11 Aug 2026 · sale | $440 888 | 2 438 | $180,84 |
| feld michael27 Jul 2026 · sale | $11 785 | 75 | $157,13 |
| feld michael26 Jun 2026 · sale | $11 460 | 75 | $152,80 |
| garrison michael david24 Jun 2026 · sale | $160 226 | 1 100 | $145,66 |
| garrison michael david10 Jun 2026 · sale | $166 628 | 1 100 | $151,48 |
| polen thomas e jr1 Jun 2026 · sale | $404 511 | 2 764 | $146,35 |
| feld michael26 May 2026 · sale | $11 051 | 75 | $147,35 |
| feld michael27 Apr 2026 · sale | $11 244 | 74 | $151,94 |
| feld michael26 Mar 2026 · sale | $11 762 | 75 | $156,83 |
| feld michael26 Feb 2026 · sale | $13 638 | 75 | $181,84 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 25 Sep 1963
- Website
- www.bd.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
EWEdwards Lifesciences | $107,11 | 56★★★★★★★★would watch | 60,3 | +13,4% | 15,2% |
IDXXIdexx Laboratories | $700,65 | 83★★★★★★★★★would consider | 47,2 | +11,9% | 25,4% |
BSXBoston Scientific | $43,69 | 83★★★★★★★★★would consider | 18,4 | +8,9% | 16,6% |
HUMHumana | $461,25 | 61★★★★★★★★would watch | 44,0 | +22,0% | 0,8% |
CAHCardinal Health | $283,85 | no score | 35,7 | — | — |
Ratio — a score by our methodology, not an investment recommendation.




